结核分枝杆菌耐药分子机制的研究进展
Research Progress on Molecular Mechanism of Drug Resistance of Mycobacterium tuberculosis
摘要: 目前许多地区结核病的发病率和病死率出现上升现象，但抗结核药物的泛滥及不合理应用，所致耐药结核分枝杆菌的出现，阻碍了结核病的诊断和治疗。因此了解结核分枝杆菌耐药分子机制和常见药物耐药分子机制，对制定有效的治疗方案，及时诊断、有效治疗结核病，改善结核患者预后具有重大意义。本文对结核分枝杆菌的耐药分子机制及常用抗结核药物的耐药分子机制进行总结，以为临床提供参考。
Abstract: At present, the incidence and mortality of tuberculosis are increasing in many areas, but the proliferation and unreasonable application of anti-tuberculosis drugs have led to the emergence of drug-resistant Mycobacterium tuberculosis, which has hindered the diagnosis and treatment of tuberculosis. Therefore, understanding the molecular mechanism of drug resistance and common drug resistance of Mycobacterium tuberculosis is of great significance for formulating effective treatment programs, timely diagnosis and effective treatment of tuberculosis, and improving the prognosis of tuberculosis patients. This article summarizes the drug-resistant molecular mechanism of Mycobacterium tuberculosis and the drug-resistant molecular mechanisms of commonly used anti-tuberculosis drugs, so as to provide clinical reference.
文章引用：杨兰, 吴秋莲. 结核分枝杆菌耐药分子机制的研究进展[J]. 临床医学进展, 2020, 10(7): 1292-1297. https://doi.org/10.12677/ACM.2020.107196

参考文献

[1] 尤媛媛, 任鹏飞, 陈裕. 河南省传染病医院耐多药结核病患者危险因素分析[J]. 河南医学研究, 2020, 29(12): 2122-2124.
[2] 张懿行, 王伟炳, 李小攀, 等. 454例不规则治疗肺结核患者复发的相关因素分析[J]. 上海预防医学, 2019, 31(12): 1015-1019.
[3] Hawn, T.R., Day, T.A., Scriba, T.J., et al. (2014) Tuberculosis Vaccines and Prevention of Infection. Microbiology and Molecular Biology Reviews, 78, 650-671. [Google Scholar] [CrossRef] 
[4] 韦媛媛, 杨帆, 汤杰, 等. 抗结核药物的研究进展[J]. 中国药科大学学报, 2020, 51(2): 231-239.
[5] Schito, M., Migliori, G.B., Fletcher, H.A., et al. (2015) Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. Clinical Infectious Diseases, 61, S102-S118. [Google Scholar] [CrossRef] [PubMed]
[6] Dheda, K., Gumbo, T., Gandhi, N.R., et al. (2014) Global Control of Tuberculosis: From Extensively Drug-Resistant to Untreatable Tuberculosis. The Lancet Respiratory Medicine, 2, 321-338. [Google Scholar] [CrossRef] 
[7] 闫莉, 关福源, 钟明浩, 等. 2018年结核病耐药情况及影响因素分析[J]. 中国实验诊断学, 2020, 24(4): 539-542.
[8] 邢小微. 宏基因组高通量测序对中枢神经系统感染性疾病的诊断价值研究[D]: [博士学位论文]. 北京: 中国人民解放军医学院, 2019.
[9] 李勇. 耐药结核病的研究进展[J]. 中国处方药, 2019, 17(4): 21-22.
[10] Churchyard, G., Kim, P., Shah, N.S., et al. (2017) What We Know about Tuberculosis Transmission: An Overview. The Journal of Infectious Diseases, 216, S629-S635. [Google Scholar] [CrossRef] [PubMed]
[11] 王仲元. 耐药结核病的研究进展[J]. 传染病信息, 2018, 31(1): 19-23.
[12] 亢鸿飞. 结核融合蛋白疫苗FdxA-Hrp1的构建及对家兔肺部卡介苗潜伏感染模型的治疗作用研究[D]: [硕士学位论文]. 兰州: 兰州大学, 2014.
[13] Mathema, B., Andrews, J.R., Cohen, T., et al. (2017) Drivers of Tuberculosis Transmission. The Journal of Infectious Diseases, 216, S644-S653. [Google Scholar] [CrossRef] [PubMed]
[14] 闫莉, 钟明浩, 关福源, 等. 结核分枝杆菌对一线抗结核药物的耐药情况分析[J]. 中国实验诊断学, 2020, 24(3): 381-384.
[15] Nahid, P., Dorman, S.E., Alipanah, N., et al. (2016) Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases, 63, e147-e195. [Google Scholar] [CrossRef] [PubMed]
[16] Zhu, C., Liu, Y., Hu, L., et al. (2018) Molecular Mechanism of the Synergistic Activity of Ethambutol and Isoniazid against Mycobacterium tuberculosis. The Journal of Biological Chemistry, 293, 16741-16750. [Google Scholar] [CrossRef] 
[17] 刘海涛, 姜小红. 一线抗结核药物治疗初治耐多药肺结核的效果及转归[J]. 临床医药文献电子杂志, 2020, 7(13): 174.
[18] Isakova, J., Sovkhozova, N., Vinnikov, D., et al. (2018) Mutations of rpoB, katG, inhA and ahp Genes in Rifampicin and Isoniazid-Resistant Mycobacterium tuberculosis in Kyrgyz Republic. BMC Microbiology, 18, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
[19] Torres, J.N., Paul, L.V., Rodwell, T.C., et al. (2015) Novel katG Mutations Causing Isoniazid Resistance in Clinical M. tuberculosis Isolates. Emerging Microbes & Infections, 4, 1-9. [Google Scholar] [CrossRef] [PubMed]
[20] 王晓英, 张汇征, 罗明, 等. 结核分枝杆菌异烟肼和丙硫异烟胺耐药及其交叉耐药相关机制研究进展[J]. 中国人兽共患病学报, 2020, 36(3): 234-238+260.
[21] Siu, G.K.H., Yam, W.C., Zhang, Y., et al. (2014) An Upstream Truncation of the furA-katG Operon Confers High-Level Isoniazid Resistance in a Mycobacterium tuberculosis Clinical Isolate with No Known Resistance-Associated Mutations. Antimicrobial Agents and Chemotherapy, 58, 6093-6100. [Google Scholar] [CrossRef] 
[22] Bollela, V.R., Namburete, E.I., Feliciano, C.S., et al. (2016) Detection of katG and inhA Mutations to Guide Isoniazid and Ethionamide Use for Drug-Resistant Tuberculosis. International Journal of Tuberculosis and Lung Disease, 20, 1099-1104. [Google Scholar] [CrossRef] [PubMed]
[23] Richardson, M., Kirkham, J., Dwan, K., Sloan, D.J., et al. (2019) NAT2 Variants and Toxicity Related to Anti-Tuberculosis Agents: A Systematic Review and Meta-Analysis. International Journal of Tuberculosis and Lung Disease, 23, 293-316. [Google Scholar] [CrossRef] [PubMed]
[24] Cao, R., Teskey, G., Islamoglu, H., et al. (2018) Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis. Antimicrobial Agents and Chemotherapy, 62, e01132-18. [Google Scholar] [CrossRef] 
[25] Wang, Y., Li, Q., Gao, H., et al. (2019) The Roles of rpsL, rrs, and gidB Mutations in Predicting Streptomycin-Resistant Drugs Used on Clinical Mycobacterium tuberculosis Isolates from Hebei Province, China. International Journal of Clinical and Experimental Pathology, 12, 2713-2721.
[26] Hlaing, Y.M., Tongtawe, P., Tapchaisri, P., et al. (2017) Mutations in Streptomycin Resistance Genes and Their Relationship to Streptomycin Resistance and Lineage of Mycobacterium tuberculosis Thai Isolates. Tuberculosis and Respiratory Diseases (Seoul), 80, 159-168. [Google Scholar] [CrossRef] [PubMed]
[27] Zheng, R., Zhu, C., Guo, Q., et al. (2014) Pyrosequencing for Rapid Detection of Tuberculosis Resistance in Clinical Isolates and Sputum Samples from Re-Treatment Pulmonary Tuberculosis Patients. BMC Infectious Diseases, 14, Article No. 200. [Google Scholar] [CrossRef] [PubMed]
[28] 梁晨, 张旭霞, 邢青, 等. 北京基因型结核分枝杆菌的流行及与二线抗结核药物耐药性的相关性[J]. 中华结核和呼吸杂志, 2020, 43(4): 356-361.
[29] 苏日娜. 氟喹诺酮类药物治疗耐多药结核病临床疗效研究[J]. 中国实用医药, 2020, 15(11): 125-126.
[30] 彭芝. 喹诺酮类药物用于结核病治疗的疗效观察[J]. 中国社区医师, 2019, 35(35): 58+60.
[31] Kandler, J.L., Mercante, A.D., Dalton, T.L., et al. (2018) Validation of Novel Mycobacterium tuberculosis Isoniazid Resistance Mutations Not Detectable by Common Molecular Tests. Antimicrobial Agents and Chemotherapy, 62, e00974-18. [Google Scholar] [CrossRef] 
[32] Vilchèze, C. and Jacobs Jr., W.R. (2014) Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. In: Hatfull, G.F. and Jacobs Jr., W.R., Eds., Molecular Genetics of Mycobacteria, 2nd Edition, John Wiley & Sons, Inc., Hoboken, 431-453. [Google Scholar] [CrossRef] 
[33] Cliff, J.M., Kaufmann, S.H.E., McShane, H., et al. (2015) The Human Immune Response to Tuberculosis and Its Treatment: A View from the Blood. Immunological Reviews, 264, 88-102. [Google Scholar] [CrossRef] [PubMed]
[34] 毛丹, 张磊. 贝达喹啉专利申请状况分析[J]. 中国新药杂志, 2020, 29(4): 367-371.
[35] Calvert, M.B., Furkert, D.P., Cooper, C.B., et al. (2020) Synthetic Approaches towards Bedaquiline and Its Derivatives. Bioorganic & Medicinal Chemistry Letters, 30, Article ID: 127172. [Google Scholar] [CrossRef] [PubMed]
[36] Turner, J. and Torrelles, J.B. (2018) Mannose-Capped Lipoarabinomannan in Mycobacterium tuberculosis Pathogenesis. Pathogens and Disease, 76, fty026. [Google Scholar] [CrossRef] [PubMed]
[37] Amicosante, M., D’Ambrosio, L., Munoz, M., et al. (2017) Current Use and Acceptability of Novel Diagnostic Tests for Active Tuberculosis: A Worldwide Survey. Jornal Brasileiro de Pneumologia, 43, 380-392. [Google Scholar] [CrossRef] [PubMed]
[38] Gong, W., Liang, Y. and Wu, X. (2018) The Current Status, Challenges, and Future Developments of New Tuberculosis Vaccines. Human Vaccines & Immunotherapeutics, 14, 1697-1716. [Google Scholar] [CrossRef] [PubMed]

为你推荐